EGFR and colorectal cancer: Currently, the treatment of colorectal cancer in the first line setting using targeted therapy is limited to anti-VEGF therapy (bevacizumab, aflibercept) or anti-EGFR therapy (cetuximab, panitumumab) in combination with an oxaliplatin based therapy.